An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1724-1728

  Zlotta, Alexandre R ^a   Remzi, Mesut ^a   Snow, Peter B ^a   Schulman, Claude C ^a   Marberger, Michael ^a   Djavan, Bob ^a  

^a NONE

Author keywords

Neoplasm staging; Neural networks (computer); Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SERUM; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0037405578     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000062548.28015.f6     Document Type: Article

References (20)

1. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. and Walsh, P. C.: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year John Hopkins experience. Urol Clin North Am, 28: 555, 2001
2. Bostwick, D. G.: Staging prostate cancer - 1997: current methods and limitations. Eur Urol, suppl., 32: 2, 1997
3. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
4. Blute, M. L., Bergstalh, E. J., Partin, A. W., Walsh, P. C., Kattan, M. W., Scardino, P. T. et al: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol, 164: 1591, 2000
5. Douglas, T. H. and Moul, J. W.: Applications of neural networks in urologic oncology. Semin Urol Oncol, 16: 35, 1998
6. Tu, J. V.: Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcome. J Clin Epidemiol, 49: 1225, 1996
7. Djavan, B., Remzi, M., Zlotta, A., Seitz, C., Snow, P. and Marberger, M.: Novel artificial neural network for early detection of prostate cancer. J Clin Oncol, 20: 921, 2002
8. Partin, A. W., Mangold, L. A., Lamm, D. M., Walsh, P. C., Epstein, J. I. and Pearson, J. D.: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 58: 843, 2001
9. Finne, P., Finne, R., Auvinen, A., Juusela, H., Aro, J., Maattanen, L. et al: Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology, 56: 418, 2000
10. Snow, P. B., Smith, D. S. and Catalona, W. J.: Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol, 152: 1923, 1994
11. Douglas, T. H., Connelly, R. R., McLeod, D. G. and Moul, J. W.: Neural network analysis of pre-operative and post-operative variables to predict pathological stage and recurrence following radical prostatectomy. J Urol, suppl., 155: 487A, abstract 706, 1996
12. Ziada, A. M., Lisle, T. C., Snow, P. B., Levine, R. F., Miller, G. and Crawford, E. D.: Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathological stage and biochemical failure using an artificial neural network. Cancer, 91: 1653, 2001
13. Han, M., Snow, P. B., Brandt, J. M. and Partin, A. W.: Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer, 91: 1661, 2001
14. Djavan, B., Kadesky, K., Klopukh, B., Marberger, M. and Roehrborn, C. G.: Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol, 33: 261, 1998
15. Zlotta, A. R., Djavan, B., Petein, M., Susani, M., Marberger, M. and Schulman, C. C.: Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml. J Urol, 160: 2089, 1998
16. Haese, A., Graefen, M., Steuber, T., Becker, C., Pettersson, K., Piironen, T. et al: Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate, 49: 101, 2001
17. Moul, J. W., Kane, C. J. and Malkowicz, S. B.: The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am, 28: 459, 2001
18. Wilkinson, B. A. and Hamdy, F. C.: State-of-the-art staging in prostate cancer. BJU Int, 87: 423, 2001
19. Egan, A. J. M. and Bostwick, D. G.: Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance of multivariate analysis. Am J Surg Pathol, 21: 1496, 1997
20. Ravery, V., Schmid, H. P., Toublanc, M. and Boccon-Gibod, L.: Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer, 78: 1079, 1996